News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genetronics Biomedical (GEB) Initiates Pancreatic Cancer Clinical Trial Using Its MedPulser Tumor Ablation System


10/19/2005 5:12:53 PM

SAN DIEGO--(BUSINESS WIRE)--March 1, 2005-- Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has initiated a Phase I clinical trial to treat pancreatic cancer using its MedPulser(R) Tumor Ablation System. The FDA has granted Genetronics orphan designation for this indication. The primary endpoint of this FDA-approved study is to determine the safety profile of the MedPulser(R) electroporation therapy in conjunction with intralesionally-injected bleomycin for the treatment of unresectable or incurable locally advanced pancreatic cancer. The secondary endpoints are to assess objective tumor response, patient pain, and weight loss over 24 weeks following electroporation therapy. Genetronics aims to complete enrollment of up to 12 patients by the end of 2005.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES